Sofinnova leads £6m investment in Mission Therapeutics

Also participating in the round are Imperial Innovations, which provided £1.3m, SR One and Roche Venture Fund. Imperial Innovations owns a 15.7% stake in the company going forward.

The funding will support the company as it looks to further progress in its drug development operations.

Company
Mission Therapeutics is a spin-out from the University of Cambridge and is developing a platform of technologies for the discovery and development of modulators of enzymes involved in cancer and other diseases.

Founded in 2011, the company is based at the Babraham Research Campus, seven miles south of Cambridge.

People
Susan Searle is CEO of Imperial Innovations.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• UK / Ireland
• Healthcare
• Early-stage
• Sofinnova Partners
• United Kingdom